GSK beats Q4 earnings estimates, lifts 2031 sales target GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine. Business • 05 Feb
GSK beats Q4 earnings estimates, lifts 2031 sales target GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine. Business • 05 Feb
GSK reports Q4 profit, sales beat Wall Street estimates GSK has today beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix. Business • 01 Feb 23
GSK reports Q4 profit, sales beat Wall Street estimates GSK has today beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix. Business • 01 Feb 23
GSK to name consumer healthcare unit 'Haleon' GlaxoSmithKline said today that its consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever. Business • 22 Feb 22
GSK to name consumer healthcare unit 'Haleon' GlaxoSmithKline said today that its consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever. Business • 22 Feb 22
Unilever says GSK consumer arm 'strong strategic fit' Unilever today signalled it would pursue a deal for GlaxoSmithKline's consumer health business, calling it a "strong strategic fit" after its £50 billion offer was rejected, sending its shares down 6%. Business • 17 Jan 22
Unilever says GSK consumer arm 'strong strategic fit' Unilever today signalled it would pursue a deal for GlaxoSmithKline's consumer health business, calling it a "strong strategic fit" after its £50 billion offer was rejected, sending its shares down 6%. Business • 17 Jan 22
Former Tesco boss Lewis to chair GSK health spin-off GlaxoSmithKline has today named former Tesco boss Dave Lewis as non-executive chair designate of a new consumer healthcare company set to be created from a proposed demerger from GSK in 2022. Business • 20 Dec 21
Former Tesco boss Lewis to chair GSK health spin-off GlaxoSmithKline has today named former Tesco boss Dave Lewis as non-executive chair designate of a new consumer healthcare company set to be created from a proposed demerger from GSK in 2022. Business • 20 Dec 21
Sanofi sees coronavirus vaccine priced below €10 A coronavirus vaccine that Sanofi is developing with GlaxoSmithKline is likely to be priced at less than €10 per shot if it is approved for use, Sanofi's chief in France has said. Business • 07 Sep 20
Sanofi sees coronavirus vaccine priced below €10 A coronavirus vaccine that Sanofi is developing with GlaxoSmithKline is likely to be priced at less than €10 per shot if it is approved for use, Sanofi's chief in France has said. Business • 07 Sep 20
GSK's quarterly profit misses as stockpiling eases GlaxoSmithKline fell short of quarterly expectations for profit today, as sales of its existing vaccines fell and stockpiling of pain and lung medication tapered as countries eased coronavirus-induced lockdowns. Business • 29 Jul 20
GSK's quarterly profit misses as stockpiling eases GlaxoSmithKline fell short of quarterly expectations for profit today, as sales of its existing vaccines fell and stockpiling of pain and lung medication tapered as countries eased coronavirus-induced lockdowns. Business • 29 Jul 20
UK secures 60 million doses of Sanofi/GSK vaccine The UK has signed a deal for up to 60 million doses of a possible Covid-19 vaccine being developed by Sanofi and GlaxoSmithKline - its fourth such arrangement as the race to tame the pandemic heats up. Business • 29 Jul 20
UK secures 60 million doses of Sanofi/GSK vaccine The UK has signed a deal for up to 60 million doses of a possible Covid-19 vaccine being developed by Sanofi and GlaxoSmithKline - its fourth such arrangement as the race to tame the pandemic heats up. Business • 29 Jul 20
Sanofi eyes approval of Covid-19 vaccine by H1 2021 French drugmaker Sanofi said today it expects to get approval for the potential Covid-19 vaccine it is developing with Britain's GlaxoSmithKline by the first half of next year, faster than previously anticipated. Business • 23 Jun 20
Sanofi eyes approval of Covid-19 vaccine by H1 2021 French drugmaker Sanofi said today it expects to get approval for the potential Covid-19 vaccine it is developing with Britain's GlaxoSmithKline by the first half of next year, faster than previously anticipated. Business • 23 Jun 20
GSK to make 1 billion doses of virus vaccine booster GlaxoSmithKline, the world's largest vaccine maker, has laid out plans to produce 1 billion doses of vaccine efficacy boosters for Covid-19 shots next year. Business • 28 May 20
GSK to make 1 billion doses of virus vaccine booster GlaxoSmithKline, the world's largest vaccine maker, has laid out plans to produce 1 billion doses of vaccine efficacy boosters for Covid-19 shots next year. Business • 28 May 20
GSK does not see mass-produced vaccine before mid-2021 GlaxoSmithKline, the world's largest vaccine maker, said the global push to develop an immunisation against the coronavirus would not lead to widely available products before the second half of next year. Business • 29 Apr 20
GSK does not see mass-produced vaccine before mid-2021 GlaxoSmithKline, the world's largest vaccine maker, said the global push to develop an immunisation against the coronavirus would not lead to widely available products before the second half of next year. Business • 29 Apr 20
Purdue deal to rank among biggest in pharma history OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the US opioid crisis. Business • 16 Sep 19
Purdue deal to rank among biggest in pharma history OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the US opioid crisis. Business • 16 Sep 19
Thermo Fisher buys GsK's Cork facility for €90m Thermo Fisher Scientific has agreed to buy a manufacturing site in Cork from GlaxosmithKline for €90m in a deal which will see the company's 400 employees transfer to its new owners. Business • 16 May 19
Thermo Fisher buys GsK's Cork facility for €90m Thermo Fisher Scientific has agreed to buy a manufacturing site in Cork from GlaxosmithKline for €90m in a deal which will see the company's 400 employees transfer to its new owners. Business • 16 May 19
GSK expects shingles drug sales to exceed $1.3 billion GlaxoSmithKline has forecast 2019 sales of its fast-growing shingles vaccine Shingrix to be "significantly" more than £1 billion today as the drugmaker outpaced first quarter forecasts. Business • 01 May 19
GSK expects shingles drug sales to exceed $1.3 billion GlaxoSmithKline has forecast 2019 sales of its fast-growing shingles vaccine Shingrix to be "significantly" more than £1 billion today as the drugmaker outpaced first quarter forecasts. Business • 01 May 19
GSK and Pfizer to combine consumer health businesses GlaxoSmithKline plans to split into two businesses - one for prescription drugs and vaccines, the other for over-the-counter products - after forming a new joint venture with Pfizer's consumer health division. Business • 19 Dec 18
GSK and Pfizer to combine consumer health businesses GlaxoSmithKline plans to split into two businesses - one for prescription drugs and vaccines, the other for over-the-counter products - after forming a new joint venture with Pfizer's consumer health division. Business • 19 Dec 18
GSK buys Novartis stake in consumer healthcare venture GlaxoSmithKline said today it will buy Novartis's 36.5% stake in their consumer healthcare joint venture for $13 billion in cash, and will also begin a strategic review of some other businesses. Business • 27 Mar 18
GSK buys Novartis stake in consumer healthcare venture GlaxoSmithKline said today it will buy Novartis's 36.5% stake in their consumer healthcare joint venture for $13 billion in cash, and will also begin a strategic review of some other businesses. Business • 27 Mar 18
GSK pulls out of $20 billion race for Pfizer asset GlaxoSmithKline has withdrawn from the race to buy Pfizer's consumer healthcare business, the British drugs company said today. Business • 23 Mar 18
GSK pulls out of $20 billion race for Pfizer asset GlaxoSmithKline has withdrawn from the race to buy Pfizer's consumer healthcare business, the British drugs company said today. Business • 23 Mar 18
GSK's new CEO to get 25% less after pay policy review Incoming GlaxoSmithKline chief executive Emma Walmsley, the first woman to lead a top global drugmaker, will get a pay package worth a quarter less than her predecessor. Business • 15 Mar 17
GSK's new CEO to get 25% less after pay policy review Incoming GlaxoSmithKline chief executive Emma Walmsley, the first woman to lead a top global drugmaker, will get a pay package worth a quarter less than her predecessor. Business • 15 Mar 17
GlaxoSmithKline sees big windfall as pound slides Drugmaker GlaxoSmithKline said it expected even bigger profit gains in 2016 thanks to a weak pound, which has continued to fall after Britain's vote in June to leave the European Union. Business • 26 Oct 16
GlaxoSmithKline sees big windfall as pound slides Drugmaker GlaxoSmithKline said it expected even bigger profit gains in 2016 thanks to a weak pound, which has continued to fall after Britain's vote in June to leave the European Union. Business • 26 Oct 16
GlaxoSmithKline names Walmsley as new CEO GlaxoSmithKline has appointed Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates. Business • 20 Sep 16
GlaxoSmithKline names Walmsley as new CEO GlaxoSmithKline has appointed Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates. Business • 20 Sep 16
New drugs help GSK offset drag of Advair sales Growing demand for new drugs helped GlaxoSmithKline beat forecasts for fourth-quarter earnings by a small margin, offsetting a continued slide in sales of its older Advair respiratory medicine. Business • 03 Feb 16
New drugs help GSK offset drag of Advair sales Growing demand for new drugs helped GlaxoSmithKline beat forecasts for fourth-quarter earnings by a small margin, offsetting a continued slide in sales of its older Advair respiratory medicine. Business • 03 Feb 16
GSK sees quarterly profit soar after Novartis deal British drugmaker GlaxoSmithKline said its net profit rocketed in the first quarter on a vast exceptional gain following a deal with Swiss peer Novartis. Business • 06 May 15
GSK sees quarterly profit soar after Novartis deal British drugmaker GlaxoSmithKline said its net profit rocketed in the first quarter on a vast exceptional gain following a deal with Swiss peer Novartis. Business • 06 May 15
EU gives conditional backing to Novartis, GSK deal The EU has approved mega deals involving drugmakers Novartis and GlaxoSmithKline, provided they sell off assets in the vaccines and consumer health businesses. Business • 28 Jan 15
EU gives conditional backing to Novartis, GSK deal The EU has approved mega deals involving drugmakers Novartis and GlaxoSmithKline, provided they sell off assets in the vaccines and consumer health businesses. Business • 28 Jan 15
GSK drops plan to sell off older drugs business GlaxoSmithKline has decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. Business • 05 Dec 14
GSK drops plan to sell off older drugs business GlaxoSmithKline has decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. Business • 05 Dec 14
Medtronic gets US clearance to buy Covidien US competition authorities have approved a pair of major deals in the medical field, including Medtronic's purchase of Covidien. Business • 27 Nov 14
Medtronic gets US clearance to buy Covidien US competition authorities have approved a pair of major deals in the medical field, including Medtronic's purchase of Covidien. Business • 27 Nov 14
